Cross-talk between G protein-coupled receptors (GPCR) is known to occur at multiple levels, including receptor heterodimerization and intracellular signaling. This study tested the hypothesis that GPCR cross-talk occurs at the transcriptional level. 
T he kallikrein-kinin and renin-angiotensin systems (KKS and RAS, respectively) are key regulators of cardiovascular and renal homeostasis. The balance between these two systems affects salt sensitivity, blood volume, vascular reactivity, and growth and development (reviewed in references [1] [2] [3] ). The most widely recognized cross-talk between the KKS and RAS is at the level of the angiotensin-converting enzyme. More recently, physical and functional interactions between the receptors for angiotensin II (AngII) (AT 1 R) and bradykinin (B2R) have been reported, adding another layer of cross-talk between the RAS-KKS cascades. AT 1 R and B2R form heterodimers in cultured cells and intact tissues, and the receptor complex signals as a "super" AT 1A receptor (4, 5) . Infusion of subpressor dosages of AngII upregulates cardiac myocyte BdkrB2 gene expression in mice (6) . Furthermore, treatment of vascular smooth muscle cells in culture with AngII produces a time-dependent induction of BdkrB2 mRNA, an effect that is inhibited by AT 1 R blockade (7) . However, the mechanisms whereby AngII regulates BdkrB2 gene expression are not fully understood, and whether AT 1 R-B2R cross-talk operates in other AngII target tissues, such as the kidney, is not entirely clear.
We previously demonstrated that the BdkrB2 promoter is regulated by a highly conserved cis-acting module that represents the binding sites for the transcription factors p53 and cAMP response element binding protein (CREB), located at nucleotide positions Ϫ44 to Ϫ69 relative to the transcription start site (8 -10) . The BdkrB2 modular enhancer drives reporter expression in mouse renal inner medullary collecting duct (IMCD3) cells but is considerably weaker in other cell types (10) . Upon activation, CREB is phosphorylated on Serine 133 (p-CREB), a modification that facilitates recruitment of a coactivator, CREB-binding protein (CBP/p300) (11, 12) . In addition to bridging CREB with the basal transcription machinery, CBP/p300 acetylates promoter-associated histones (13) , relaxes local chromatin structure, and allows better access of transcription factors to the cis-regulatory elements (14) . It has also been shown that p-CREB interacts with and recruits p53 to target promoters that contain composite target sites (15) . Given that AngII stimulates the phosphorylation of p53 (on serine 15) (16, 17) and CREB (on serine 133) (18) , we hypothesized that AngII signaling converges on the p53-CRE enhancer to stimulate BdkrB2 gene transcription. Our results indicate that AT 1 R signaling activates CREB phosphorylation and in vivo assembly of p-CREB on the BdkrB2 promoter in conjunction with histone hyperacetylation. AngII stimulates BdkrB2 gene transcription in IMCD3 cells via the AT 1 R. Studies in genetically targeted mice demonstrated that control of BdkrB2 gene by AngII occurs in the renal medulla and is mediated via the AT 1 R subtype A (AT 1A ) rather than AT 1B . Thus, under conditions of augmented AngII and AT 1 R signaling, B2R expression will be enhanced, thereby maintaining a balance of these two powerful counterregulatory systems.
Materials and Methods

Animals and Tissues
The animal study protocol was performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Tulane University and Louisiana State University. Tissues were harvested from adult male wild-type,
and Agtr 1A/B Ϫ/Ϫ mice (3 mo of age; n ϭ 3 each). Details of breeding and genotyping were previously published (19) . Total RNA was extracted from the heart, kidney medulla, and kidney cortex using the Trizol reagent (Invitrogen, Carlsbad, CA). Total RNA from mouse embryonic kidneys (E13.5 d) was extracted with RNAqueous-4PCR Kit (Ambion, Austin, TX).
Cell Culture
IMCD3 cells (20) were obtained from American Type Culture Collection (Rockville, MD) and maintained in DMEM/F-12 that contained 10% FBS (Invitrogen) at 37°C in a humidified incubator with 5% CO 2 . The cells were plated in duplicate in six-well plates at 2 to 3 ϫ 10 5 cells/well 2 d before AngII treatment. For avoidance of the confounding effects of growth factors that were present in the serum on B2R expression, IMCD3 cells were grown in serum-free medium for 24 h before treatment. Icatibant (a specific B2R antagonist, 10 Ϫ6 M) and candesartan (a specific AT1 receptor antagonist, 10 Ϫ6 M) were chosen on the basis of their ability to inhibit the hemodynamic and growthrelated effects of exogenously infused intravenous BK or AngII (21) (22) (23) (24) (25) .
Immunofluorescence Staining
IMCD3 cells were cultured on chamber slides to 40 to 50% confluence, washed once with ice-cold 1ϫ PBS, and fixed in ice-cold 4% paraformaldehyde/0.1% glutaraldehyde solution at room temperature for 10 min. After removal of the fixatives, cells were permeabilized with ice-cold PBS that contained 1% Triton X-100 for 15 min at room temperature and blocked with ice-cold PBS that contained 1% BSA for 10 min. Cells were incubated with a polyclonal rabbit B2R antibody (AS276-283, diluted 1:500, from Dr. Muller-Esterl, Mainz, Germany) (26) overnight at 4°C followed by extensive washes with PBS that contained 1% BSA. The cells were subsequently incubated with secondary antibody (Alexa Fluor 594; Molecular Probes, Eugene, OR; 1:200) for 2 h at room temperature and subjected to extensive washes thereafter. Cells were then incubated with the AT 1 R antibody (sc-1173; Santa Cruz Biotechnology, Santa Cruz, CA; 1:200) (27) overnight at 4°C followed by extensive washes with PBS that contained 1% BSA. Subsequently, the cells were incubated with secondary antibody (Alexa Fluor 488; Molecular Probes; 1:2000) for 2 h at room temperature. After extensive washes, the sections were covered with fluorescence mounting medium that contained a nuclear stain, DAPI. Immunofluorescence images were obtained with an Olympus BX51TRF microscope and an integrated Magnafire SP Digital "Firewire" Camera System (Olympus American Inc., Center Valley, PA). Negative controls included cells that were incubated in the absence of primary antibodies (single or both).
Western Blot Analysis
Immunoblotting was performed as described previously (10) . Primary antibodies were a polyclonal anti-B2R (diluted 1:1500), CREB (Cell Signaling, Danvers, MA; 48H2, 9197; 1:1000), and p-CREB (Upstate Biotechnology, Lake Placid, NY; 06-519; 1:500). After three washes in PBS/Tween, the nitrocellulose membrane was exposed for 1 h at room temperature to the secondary antibody (horseradish peroxidaselinked goat anti-rabbit IgG). Immunoreactive bands were visualized using the ECL detection system (Amersham, Piscataway, NJ). The immunoblots were exposed to Hyperfilm-ECL films. The blots were then reprobed with a ␤-actin antibody (Sigma, St. Louis, MO; 1:4000) as a loading control.
Reverse Transcriptase-PCR
After DNAse I digestion, 2 to 3 g of total RNA was reversetranscribed using SuperScript II Reverse Transcriptase (Invitrogen) in a 22-l volume. One to three microliters of the reaction volume was used in a PCR volume of 25 l. The primer sequences for BdkrB2 were as follows: Upstream 5Ј-AGA ACC TCT TTG TCC TCA GCG-3Ј; downstream 5Ј-CGT CTG GAC CTC CTT GAA CT-3Ј. PCR was performed at 94°C for 50 s, 60°C for 60 s, and 72°C for 90 s, 1.0 mM MgCl 2 , 30 cycles. The product size was 572 bp. The primer sequences for Agtr1 A were as follows: Upstream 5Ј-GCA TCA TCT TTG TGG TGG G-3Ј; downstream 5Ј-GAA GAA AAG CAC AAT CGC C-3Ј. PCR was performed at 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min, 2.0 mM MgCl 2 , 35 cycles. The product size was 641 bp. The primer sequences for Agtr2 were as follows: Upstream 5Ј-AGT GCA TGC GGG AGC TG-3Ј; downstream 5Ј-GAC AAC AAA ACA GTG AG-3Ј. PCR was performed at 94°C for 1 min, 53°C for 1 min, and 72°C for 2 min, 1.5 mM MgCl 2 , 35 cycles. The product size was 309 bp. The primer sequences for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as follows: Upstream 5Ј-CCC CTG GCC AAG GTC ATC CAT GAC AAC TTT-3Ј; downstream 5Ј-GGC CAT GAG GTC CAC CAC CCT GTT GCT GTA-3Ј. PCR was performed at 94°C for 50 s, 55°C for 50 s, and 72°C for 90 s, 1.5 mM MgCl 2 , 27 cycles. The product size was 516 bp. PCR reactions were visualized on a 1% agarose gel, and densitometric analysis was performed with the ChemiImager 4400 program (Alpha Innotech, San Leandro, CA). 
Intracellular Calcium Measurements
Promoter Constructs, Transient Transfection, and Reporter Assays
The BdkrB2 Ϫ94/ϩ55-CAT promoter-reporter construct was previously described (8, 9) . The mutant BdkrB2 Ϫ94(P1mut)/CAT, Ϫ94(CREmut)/CAT, Ϫ94(P1mutCREmut)/CAT constructs were generated by introducing point mutations in the Ϫ94/ϩ55-CAT construct at the p53-binding site (P1) and CREB binding site (CRE), singly or in combination, using the QuickChange site-directed mutagenesis system (Stratagene, La Jolla, CA) (10). All constructs were subjected to DNA sequencing to verify the sequence and orientation.
IMCD3 cells that were maintained in DMEM/F-12 medium that contained 10% FBS were plated in duplicate in 3.5-cm-diameter six-well plates at 2.0 ϫ 10 5 cells/well 2 d before transfection, followed by 24 h of serum-free medium 1 d before transfection. Cells that were grown to 80% confluence were transfected with 1 g of DNA per well of each promoter-reporter construct. One microgram of DNA per well pCAT3 Basic vector (empty vector) was transfected as a control. A ␤-galactosidase vector, pSVZ (0.4 g of DNA/well; Promega, Madison, WI), was co-transfected to correct for transfection efficiency. Transfections were performed using Lipofectamine Plus Reagent (Life Technologies, Rockville, MD) according to the manufacturer's recommendations. Four hours after transfection, the medium was replaced with fresh medium in the absence of serum. Twenty-four hours after transfection, cells were either treated with AngII (10 Ϫ7 M) or left untreated, and 6 h later, cell extracts were prepared using a reporter lysis reagent (Promega). Aliquots of cell lysate were analyzed for CAT activity after normalization for protein content or ␤-galactosidase activity as described previously (9).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed using reagents and protocols from Upstate Biotechnology as described previously (10, 30) . IMCD3 cells were plated in 10-cm culture dishes and starved for 24 h before AngII treatment. After AngII stimulation (10 Ϫ7 M) for the indicated time periods, cells were incubated with 1% formaldehyde solution in growth medium for cross-linking (10 min at room temperature) followed by addition of 1 ml of 10ϫ glycine to quench unreacted formaldehyde for 5 min at room temperature. Cell pellets were resuspended in SDS lysis buffer that contained protease inhibitor and phosphatase inhibitor cocktails. DNA was sheared by sonicating the cell lysate to produce an average DNA fragment size between 200 and 1000 bp and diluted 10-fold in ChIP dilution buffer. Immunoprecipitation was performed with antibodies to p-CREB (Ser133; Upstate Biotechnology; 06-519; 20 l), CREB-1 (Santa Cruz; 240, sc-58; 25 l), acetylated H4 (Upstate Cell Signaling; 06-866; 1:150 dilution), or control normal Ig (IgG) antibodies overnight at 4°C. DNA-protein-antibody complexes were captured on protein A/G-conjugated agarose beads. DNA-protein cross-links were reversed at 65°C overnight followed by proteinase K treatment to free DNA. Immunoprecipitated DNA was purified by spin column and subjected to PCR. Sequences of the primers that were used for PCR of the mouse B2R gene that flanked the p53-CRE enhancer are as follows: Forward primer 5Ј-AGG GGG GAG GTG CCC AGG AGA GTG ATG ACA-3Ј; reverse primer 5Ј-GGT TCT GTG TTG TAG GGA GT-3Ј.
Statistical Analyses
All data are expressed as means Ϯ SEM and analyzed by t test or one-way ANOVA. All experiments were performed at least three times in duplicate. Differences between experimental groups were considered statistically significant at P Ͻ 0.05.
Results
AngII Upregulates BdkrB2 Gene Expression in Renal Collecting Duct Cells
Previous studies suggested the presence of AT 1 R and B2R in several renal cell types, including vascular (smooth muscle, juxtaglomerular, endothelial) and collecting duct cells (31, 32) . Using double-immunofluorescence staining, we show that AT 1 R and B2R are coexpressed on the cell membrane of mouse IMCD3 cells ( Figure 1A) . Control experiments that were conducted in the absence of primary antibodies revealed no specific staining (data not shown). AngII signals via two receptors, AT 1 R and AT 2 R, which are coupled to different intracellular signaling pathways. IMCD3 cells express predominantly AT 1 R transcripts; in contrast, only minimal amounts of AT 2 R mRNA were detectable ( Figure 1B Figure 2 ). Candesartan abrogated the stimulatory effect of AngII on BdkrB2 gene expression, indicating that the AngII-induced increase in BdkrB2 mRNA is mediated by the AT 1 R (Figure 2 
AngII-Stimulated BdkrB2 Is Actinomycin D Sensitive
To explore the molecular mechanisms by which AngII regulates B2R gene expression, we pretreated quiescent IMCD3 cells with the transcriptional inhibitor actinomycin D (10 Ϫ6 M) for Figure 4A ). These data suggest that AngII upregulates B2R gene expression at the transcriptional level. 
AngII Stimulates BdkrB2 Promoter Activity
In previous studies, we demonstrated that a highly conserved BdkrB2 promoter fragment that extends from Ϫ94 to ϩ55 bp, relative to the transcription start site at ϩ1, is sufficient to drive reporter CAT activity in IMCD3 cells (10) . This promoter region contains a composite cis-regulatory module for the transcription factors p53 and CREB, and cooperative interaction between the two proteins is essential for optimal BdkrB2 promoter activity (10) . Accordingly, we tested the effects of AngII on the activity of BdkrB2 Ϫ94/ϩ55-CAT promoter activity using transient transfection assays in IMCD3 cells ( Figure  4B ). The promoterless vector pCAT3Basic served as a control. Twenty-four hours after transfection, cells were treated with AngII (10 Ϫ7 M) for 6 h and whole-cell lysates were harvested and assayed for CAT activity. As shown in Figure 4 , C and D, AngII stimulated BdkrB2 promoter-driven reporter activity to 1.7 Ϯ 0.08-fold (P Ͻ 0.05 versus untreated cells; n ϭ 5), whereas the promoterless construct pCAT3Basic was not affected by AngII.
To determine the functional importance of p53 and CREB in AngII-mediated transcriptional activation, we introduced mutations in the Ϫ94/ϩ55-CAT construct at the p53(P1)-and CRE cis-regulatory elements, either singly or in combination. These mutations have been shown to inhibit the binding of p53 and CREB to their respective sites (10) . IMCD3 cells were transiently transfected with Ϫ94/ϩ55-CAT construct, the single-mutant constructs Ϫ94P1mut/CAT and Ϫ94CREmut/ CAT, and the double mutant construct Ϫ94P1mutCREmut/ CAT. Twenty-four hours after transfection, the cells were treated with AngII (10 Ϫ7 M) for 6 h. CAT assays revealed that mutations in CRE or p53 binding sites, either singly or in combination, abrogated AngII-stimulated BdkrB2 promoter activity ( Figure 5 ).
AngII Stimulates CREB Phosphorylation and Association with BdkrB2 Promoter
Multiple signal transduction pathways are known to converge on the transcription factor CREB, leading to its phosphorylation on serine 133 (33) . This posttranslational modification promotes the interaction of CREB with its co-activator, CBP/ p300, and enhances CREB transcriptional activity (11, 13) . In addition, CREB phosphorylation has been shown to facilitate the interaction of CREB with p53 and thus their co-recruitments to target promoters (15, 33) . For examination of the effect of AngII on CREB phosphorylation, IMCD3 cells were incubated with AngII (10 Ϫ7 M) and cellular lysates were harvested at various time points ranging from 0 to 60 min. The lysate was subjected to Western blotting using p-ser133-CREB or CREB antibodies. The results showed that AngII significantly increased p-CREB/CREB ratio at 30 min after stimulation ( Figure  6 , A and B). We next asked whether AngII stimulation promotes the binding of p-CREB to the endogenous BdkrB2 promoter using ChIP-PCR. As shown in Figure 6C , baseline occupancy of BdkrB2 promoter by p-CREB was minimal and comparable to background levels. This was not due to the lack of CREB binding to the promoter ( Figure 6C ). Exposure of IMCD3 cells to AngII for 15 min induced a considerable increase in p-CREB at the BdkrB2 promoter to 3.3-fold (n ϭ 2) relative to control. Consistent with the ability of p-CREB to interact with and recruit CBP/p300, this effect was associated with hyperacetylation of promoterassociated histone H4 ( Figure 6D ). These results indicate that AngII stimulates association of p-CREB with the BdkrB2 pro- Twenty-four hours after transfection, cells were treated with AngII (10 Ϫ7 M) for 6 h and cell lysate was assayed for CAT activity; untreated cells served as control. Bar graph represents the mean Ϯ SEM of CAT activity expressed relative to control (untreated). *P Ͻ 0.05 versus control (n ϭ 5). moter and localized promoter hyperacetylation, an epigenetic marker of transcriptional activation.
AngII-Treated Cells Exhibit Enhanced Intracellular B2R-Ca 2ϩ Signaling
To determine whether AngII-mediated induction of BdkrB2 gene expression is accompanied by a functional cellular response, we evaluated the effect of 24-h AngII treatment on BK-induced intracellular calcium [Ca 2ϩ ] i in IMCD3 cells. Figure  7A shows that the mean peak responses to BK (10 Ϫ9 and 10 Ϫ7 M) were ⌬23.4 Ϯ 3.9 nM and ⌬46.8 Ϯ 9.03 nM (n ϭ 8 and 6, respectively; P Ͻ 0.05) above baseline. This finding confirms that B2R is coupled to intracellular Ca 2ϩ signaling in IMCD3 cells. For testing the effect of AngII on B2R signaling, the cells were treated with AngII (10 Ϫ7 M) for 24 h before exposure to BK (10 Ϫ7 M). Untreated cells were used as a control. Figure 7B shows that the mean peak response to BK in AngII-treated cells was 87.12 Ϯ 12.45 nM above baseline, compared with 39.20 Ϯ 4.61 nM in untreated cells (n ϭ 14 and 15, respectively; P Ͻ 0.05). The B2R antagonist icatibant (10 Ϫ6 M) reduced the mean peak response to BK to 16.10 Ϯ 2.59 nM in AngII-treated cells (n ϭ 10; P Ͻ 0.05; Figure 7B ). The results indicate that AngIItreated cells respond by increasing B2R mRNA and protein synthesis as well as by enhanced membrane-associated B2R signaling. Figure 8A ). In contrast, the renal cortex showed no differences in BdkrB2 gene expression among the genotypes (data not shown). BdkrB2 mRNA levels tended to be lower in the heart of Agtr1 A Ϫ/Ϫ and Agtr1 A Ϫ/Ϫ / B Ϫ/Ϫ than in Agtr1 ϩ/ϩ and Agtr1 1B Ϫ/Ϫ mice (0.54 Ϯ 0.04 versus 0.64 Ϯ 0.02; factored for GAPDH; P ϭ 0.07; Figure 8B ). These results together with the cell culture data support the notion that BdkrB2 gene expression is under physiologic regulation by AngII.
Reduced BdkrB2 Gene Expression in Agtr1 A -Null Mice
Discussion
AngII, acting via AT 1 R, stimulates renal tubular sodium and water reabsorption and causes renal vasoconstriction. In contrast, kinins promote natriuresis and diuresis and increase renal blood flow via stimulation of B2R. Therefore, the balance between the RAS and KKS affects salt and water handling, volume homeostasis, and BP control (2) . This is well illustrated in BdkrB2 Ϫ/Ϫ mice, which are susceptible to AngII-induced hypertension (22) . AT 1 R and B2R belong to the seven-transmembrane GPCR family of receptors and are coexpressed in several cell types, including vascular and renal epithelial cells, including the renal collecting duct (31, 32) . Both short-and long-loop interactive pathways exist between the AT 1 R and B2R. In the short-loop pathway, AT 1 R and B2R communicate directly with each other. The two receptors form stable heterodimers, resulting in enhanced activation of AT 1 R signaling (4). The AT 1 R-B2R complex seems to signal as a "super AT 1 R." It is interesting that a significant increase in AT 1 R-B2R heterodimerization occurs in hypertensive preeclamptic women and is associated with a five-fold upregulation in B2R levels (5). Our findings in this study support the concept that BdkrB2 gene expression is positively regulated by AngII and that signaling via AT 1 R-B2R activates B2R expression. The long-loop pathway that connects AT 1 R and B2R receptors involves gene regulation. This cross-regulatory pathway seems to operate in cardiac/vascular smooth muscle cells and, as shown in this study, in renal collecting duct cells. Infusion of subpressor doses of AngII into wild-type mice upregulates cardiac myocyte BdkrB2 mRNA by 47% (6) . Furthermore, treatment of vascular smooth muscle cells in culture with AngII produces a time-dependent induction of BdkrB2 mRNA that is maximal at 3 h and declines to baseline by 24 h. This effect is blocked by AT 1 R antagonism (6) . This study provides new evidence that the BdkrB2 gene is a downstream target of the AT 1A R in vivo. This conclusion is based on the following find- Figure 5 . AngII activates the BdkrB2 promoter via the p53-CRE module. (A) CAT assay. Site-directed mutagenesis was used to introduce mutations in the Ϫ94/ϩ55-CAT construct at the p53(P1)-and CRE-response elements, singly or in combination. The wild-type Ϫ94/ϩ55-CAT, Ϫ94P1mut/CAT (mutant p53-binding site), Ϫ94CREmut/CAT (mutant CREB binding site), or Ϫ94P1mut.CREmut/CAT (double mutant) constructs were transfected into IMCD3 cells. Twenty-four hours after transfection, cells were treated with AngII (10 Ϫ7 M) for 6 h and cell lysate was subjected to CAT activity assay as described in Figure 4 . A control ␤-galactosidase vector, pSVZ, was co-transfected to correct for transfection efficiency. Twenty-four hours after transfection, cells were treated with AngII (10 Ϫ7 M) for 6 h and cell lysate was subjected to CAT activity assay after normalization for ␤-galactosidase activity; untreated cells as control. (B) Bar graph represents the mean Ϯ SEM of CAT activity expressed relative to control (untreated). *P Ͻ 0.05 versus Ϫ94/ CAT control (n ϭ 5). In the kidney, AT 1 R and B2R are expressed in a developmentally regulated manner, increasing from relatively low levels in the embryo to peak levels perinatally (34) . Moreover, immuno- (ser133) antibodies. PCR amplification of the immunoprecipitated genomic DNA was performed using primers that flank the p53-CRE module. In unstimulated cells, the BdkrB2 promoter is occupied by CREB, whereas the p-CREB signal is minimal. After AngII stimulation (10 Ϫ7 M, 15 min), p-CREB occupancy of the promoter is enhanced, whereas the total CREB signal remains unchanged (n ϭ 2 independent experiments). (D) ChIP assay of the BdkrB2 promoter in AngII-treated IMCD3 cells using anti-acetylated histone (Ace-H4) antibody or nonspecific IgG (control). PCR amplification of the immunoprecipitated genomic DNA was performed using primers that flank the p53-CRE module. PCR amplification of the immunoprecipitated genomic DNA revealed enrichment of Ace-H4 in AngII-treated cells 2 h after AngII stimulation as compared with untreated samples (n ϭ 3). Similar results were obtained at 4 and 6 h (data not shown). (E) Quantitative analysis of Ace-H4 enrichment on BdkrB2 promoter expressed relative to input DNA. *P Ͻ 0.05 versus control. histochemical analysis has shown that AT 1 R are more widely distributed along the nephron than previously recognized, including renal vascular smooth muscle and proximal and distal epithelial sites (31) . B2R is expressed primarily in collecting duct cells but also in the vascular and interstitial elements within the kidney (26, 32 (20) . As shown in this study, IMCD3 cells express AT 1 R and B2R mRNA and protein, whereas AT 2 R mRNA was difficult to detect. Therefore, IMCD3 cells express predominantly the AT 1 R subtype, which is compatible with the finding that AngII-induced B2R gene expression was completely abrogated by pharmacologic AT 1 R antagonism. As a GPCR, B2R generally signals through G␣ q to stimulate phospholipase C ␤ . In addition, B2R interacts with several other G proteins, including G␣ i , G␣ s , and G␣ 12/13 . BK stimulates G␣ q -sensitive phospholipase C ␤ , leading to phosphoinositide hydrolysis and intracellular free Ca 2ϩ mobilization. Increased intracellular Ca 2ϩ can in turn mediate the activation of cytosolic Ca 2ϩ -dependent endothelium nitric oxide synthase and Ca 2ϩ -sensitive phospholipase A2, thereby leading to nitric oxide and prostaglandin release (35) . Our study showed that AngII treatment amplifies the intracellular Ca 2ϩ response to bradykinin, whereas the B2R antagonist icatibant reduces the peak response to bradykinin in AngII-treated cells. Altogether, these data indicate that AngII stimulates B2R signaling in renal epithelial cells.
The BdkrB2 gene is located on human chromosome 14, mouse chromosome 12, and rat chromosome 6. The overall organization and structure of the BdkrB2 gene are generally similar in the three species: Three exons and two introns. The human and the rat but not the murine BdkrB2 genes have an alternatively spliced exon between exons 2 and 3, termed exon 2b. The coding sequence of BdkrB2 resides in exon 3 (36, 37) . Previous analysis of the rat BdkrB2 gene identified a modular enhancer located at nucleotides Ϫ44 to Ϫ82 of rat BdkrB2 promoter, which is 100% conserved between rat and mouse and 85% conserved between rat and human genes (10) . The BdkrB2 enhancer receives inputs from three transcription factors with overlapping expression in the collecting ducts, namely, p53, CREB, and KLF-4 (10). CREB phosphorylation on Ser-133 is required for optimal stimulation of BdkrB2 promoter activity through recruitment of CBP and enhancement of p53-CREB interactions. Therefore, the renal collecting duct epithelial cells contain the necessary machinery for the regulation of BdkrB2 transcription. The sequence similarities between rodent and human proximal BdkrB2 promoter regions suggest that these control factors exist in the human kidney.
This study demonstrates that AngII-induced BdkrB2 gene expression is mediated transcriptionally because it is completely blocked by actinomycin D. Moreover, a promoter-reporter construct that harbors the modular BdkrB2 enhancer is responsive to AngII stimulation. Our investigations of the signaling inputs that link the AT 1 R to the BdkrB2 enhancer revealed several important findings. First, AngII stimulates the phosphorylation of CREB on Ser-133 within 15 to 30 min, a modification that is required for the interaction of CREB with its co-activator, CBP/p300, resulting in enhanced CREB tran- Figure 8 . Reduced renal BdkrB2 gene expression in Agtr1 A knockout mice. Total RNA from renal medulla (A) or heart (B) of Agtr1 A ϩ/ϩ and Agtr1 A Ϫ/Ϫ mice was subjected to RT-PCR using mouse BdkrB2 and gapdh primers as described in Materials and Methods. Bar graphs represent the mean Ϯ SEM of BdkrB2/gapdh band intensity (n ϭ 3 per genotype). *P Ͻ 0.05 versus Agtr1 ϩ/ϩ . scriptional activity (11) . Second, as demonstrated by ChIP, AngII stimulated occupancy of the BdkrB2 promoter by activated CREB, as well as induced promoter histone hyperacetylation. These events also occurred within 30 min. Acetylation of promoter-associated nucleosomes is thought to relax the chromatin structure, thereby facilitating access of transcriptional activators to their binding sites on DNA (38) . Third, introduction of point mutations in the CRE-or p53-binding sites abrogated AngII-induced activation of the BdkrB2 promoter. Fourth, RT-PCR analysis revealed upregulated expression of BdkrB2 mRNA as early as 3 h after stimulation with AngII. On the basis of these findings, we propose a model in which AT 1 R signaling stimulates sequential series of events that lead to phosphorylation of CREB and its binding to the p53-CRE modular enhancer in the BdkrB2 promoter. Phosphorylation of CREB promotes recruitment of CBP and p53 and stimulates localized histone hyperacetylation and activation of BdkrB2 transcription in renal epithelial cells. The enhanced transcription of BdkrB2 gene leads to augmented mRNA and protein levels, which results in enhanced intracellular calcium signaling and functional responses to bradykinin.
